REGN7508 for Preventing Cancer-Associated Blood Clots
This study is testing an experimental drug called REGN7508 to see if it can prevent blood clots (Cancer-Associated Thrombosis or CAT) in adults with advanced or metastatic solid tumors. You might be eligible if you have a high risk of blood clots based on a special score (Khorana score ≥2) or certain genetic changes in your tumor. The study will compare REGN7508 to a placebo (an inactive substance) to see how well REGN7508 prevents blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE), and also to understand its side effects. The main goal is to measure the time until the first blood clot event or a serious bleeding event occurs over six months.
- Study design
- This interventional study plans to enroll 1120 participants. It compares REGN7508 to a placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for six months to track blood clot events and bleeding events.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
At a glance
Conditions
Where it's being run
14 sites across 7 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related deathThrough 6 months
- Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH) major bleeding or Clinically Relevant Non-Major (CRNM) bleedingThrough 6 months